Lung cancer treatment puzzle: which drug works best for a rare mutation?
NCT ID NCT07458919
Summary
This study aims to find out which type of targeted drug works better as the first treatment for advanced lung cancer with a specific, less common genetic change called an EGFR '19delins' mutation. It will compare older 'first-generation' drugs with newer 'third-generation' drugs. The goal is to help patients with this specific mutation live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.